CHICAGO – August 5, 2025 – bioMérieux, a global leader in in vitro diagnostics, received two 2025 IMV ServiceTrak™ Clinical Laboratory Awards for excellence in Immunoassay. These awards highlight bioMérieux’s continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories. IMV is expected to announce more awards in additional categories at the end of August.
As healthcare systems face increasing complexity and diagnostic demands, bioMérieux remains a trusted partner in supporting laboratories with high-performing technologies and responsive service. bioMérieux formally accepted the awards at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Conference including:
- (Immunoassay) Best System Performance – highest overall system functionality
- (Immunoassay) Best Service – highest satisfaction with OEM service and support
“We are honored to be recognized by IMV for the eighth consecutive year — a reflection of the dedication and excellence demonstrated by our customer support teams, in collaboration with all functions driving our product life cycle management,” said David Machenaud, bioMérieux Vice President, U.S. Customer Support Operations. “This achievement underscores our deep commitment to customer satisfaction and commercial excellence, while highlighting the culture of service excellence that defines bioMérieux. Our customers and their patients remain at the center of everything we do, and we are proud to support them with the highest standards of care.”
IMV, part of Science and Medicine Group, is a market research and business intelligence provider to the laboratory diagnostic industry. The 2025 IMV ServiceTrak™ Clinical Laboratory Awards are based on extensive customer surveys measuring satisfaction with service, system performance, training, and overall experience with diagnostic equipment vendors. bioMérieux’s recognition in these core areas reinforces their position as a leader in microbiology and infectious disease diagnostics.
Additional IMV ServiceTrak™ Clinical Laboratory awards including those across Molecular Diagnostics, ID/AST, and Blood Culture are expected to be announced in late August.
Left to right: Vice President U.S. Commercial Operations Benjamin George, Vice President North America Medical Affairs John Osiecki, Executive Vice President Clinical Operations Jennifer Zinn, North America Chief of Staff Jessica Weidner, and Vice President U.S. Marketing Stijn Bammens from bioMérieux accept IMV ServiceTrak™ awards at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo. (Jean-Marc Giboux/AP Content Services for bioMérieux)
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4 billion, with over 93% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP